Claude

What's Next

Current Price

$73.88

FY2026 P/E

7.5

Median Analyst Target

$94.00

**Buy at $73.88.** Probability-weighted value of $89 implies 20% upside. MetLife trades at 7.5x consensus FY2026 EPS of $9.86, a discount to its own 5-year average and peers, despite delivering 16% adjusted ROE and accelerating capital return. The next catalyst -- Q1 2026 earnings on May 6 -- arrives with a strong preliminary VII read ($475-525M) that should support a beat. Position size: 3-4% of portfolio.

Catalyst Calendar

No Results

The near-term setup is favorable. MetLife's April 7 8-K disclosed preliminary Q1 variable investment income of $475-525 million, well above the $400 million/quarter normalized level. This suggests strong private equity returns in Q1 and creates a likely EPS beat when full results are reported on May 6. The consensus Q1 EPS estimate of $2.21 was set before this disclosure and may not fully incorporate the VII upside.

What the market is watching most closely: Whether adjusted ROE holds above 15% in Q1 2026. This is the New Frontier's signature metric, and two consecutive quarters above 15% would build the case that MetLife's earnings quality deserves a higher multiple. Group Benefits underwriting – specifically the loss ratio – is the other key variable after the Q3 2024 wobble that spooked the market.

What is not a catalyst: Macro fear. MetLife trades at a beta of 0.73 and has demonstrated cash flow resilience through COVID, rate hikes, and market corrections. The current 11% pullback from December highs is a macro discount, not a fundamental one. Operating cash flow grew every year from FY2020 ($11.6B) to FY2025 ($18.1B) regardless of GAAP volatility.